---
title: 'Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous
  NSCLC: Real-world evidence'
date: '2025-02-05'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39907049/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250205170939&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: This real-world evidence suggests that immunochemotherapy
  generally improves OS in mNSCLC. Subgroup analysis showed no survival benefit for
  patients with ECOG >1 or bone metastasis, but a benefit for patients with M1c ...'
disable_comments: true
---
CONCLUSION: This real-world evidence suggests that immunochemotherapy generally improves OS in mNSCLC. Subgroup analysis showed no survival benefit for patients with ECOG >1 or bone metastasis, but a benefit for patients with M1c ...